Overall verdict
Buy
7.0/10
1-year performance
+57.91%
Score breakdown
Up 57.9% over 1 year, 97% of the 52-week range.
Strongest: Profitability 10.0/10. Weakest: Shareholder return 3.0/10.
16 analysts, target +0.1% vs the price.
Hinge Health, Inc. focuses on building a health system that scales and automates the delivery of care using technology. It designs its platform to address musculoskeletal system care (MSK), including acute injury, chronic pain, and post-surgical rehabilitation. The company also provides personalized and automated MSK care through AI-powered motion tracking technology and a proprietary electrical nerve stimulation wearable device. It primarily serves self-insured employers. The company was founded in 2012 and is headquartered in San Francisco, California.
Sector
Health Care
Industry
Health Care Providers and Services
Primary listing
Nyse
United States
CEO
Daniel Perez
Founded
2012
Employees
143
Revenue / employee
4.1M USD
Next earnings
November 5, 2026 (estimated)
Institutional holders
- BlackRock, Inc.4.53%
- 11.2 Capital Management, LLC3.13%
- VANGUARD PORTFOLIO MANAGEMENT LLC2.72%
- Deer Management Co. LLC2.42%
- VANGUARD CAPITAL MANAGEMENT LLC2.40%
- TWO SIGMA INVESTMENTS, LP2.29%
- FULLER & THALER ASSET MANAGEMENT, INC.2.17%
- MORGAN STANLEY2.05%
- FRANKLIN RESOURCES INC2.00%
- Other institutions49.25%
- Rest of the register27.02%
278 13F filings as of June 30, 2026: US managers above $100M, filed up to 45 days after quarter end. No insiders, no retail. A share on loan is declared by its lender and by whoever bought it from the short seller, so the total can exceed 100%.
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
96.66 USD
52-week low
30.08 USD
1-year performance
57.91%
Rising
Year-to-date performance
98.71%
Rising
Drawdown
-2.22%
Near its high
Position in the 52-week range
97% of range
Range: 29.92 USD - 35.37 USD (comparables only)
Quality and profitability
10.0/10Gross margin 84.5%, net margin 14.8%, ROIC 29.3%, ROE 29.6%.
Net margin
14.77%
Exceptional
Sector 3.21%|S&P 12.97%
Gross margin
84.49%
Exceptional
Return on equity (ROE)
29.63%
Exceptional
Sector 6.71%|S&P 16.52%
Return on invested capital (ROIC)
29.32%
Exceptional
Free cash flow margin (FCF)
39.43%
Exceptional
Profit-to-cash conversion (FCF conversion)
2.67x
Exceptional
Revenue to net income
Growth
10.0/10Revenue up 53.0% over 1 year.
Revenue (trailing 12 months)
720M USD
Revenue growth (1y)
53.00%
Hyper-growth
Revenue growth (3y)
—
EPS growth (1y)
103.97%
Hyper-growth
EPS CAGR (5y)
—
EPS revisions (3 months)
-7.11%
Sharply revised down
Valuation
3.1/10P/E 72.8x, forward P/E 47.1x, EV/EBITDA 71.8x, PEG 0.70.
P/E (TTM)
72.8x
Very expensive
Sector 27.2x|S&P 23.0x
Forward P/E
47.1x
Expensive
EV / EBITDA
71.8x
Very expensive
Sector 12.6x|S&P 14.5x
PEG
0.70
Growth unpriced
Sector 0.84|S&P 0.86
Fair value (reverse DCF)
32.65 USD
Deeply overvalued
Market cap
7.4Md USD
Financial strength
10.0/10Cash covers 6616.7% of the debt, no net debt (net cash).
Net debt / EBITDA
—
Gearing (net debt / equity)
-111.38%
Net cash
Cash
389M USD
Cash / market cap
5.23%
Tight
Cash / total debt
6616.67%
Net cash
Net debt
-384M USD
Equity
344M USD
Closed daily candles, 16 months
Last close on September 24, 2026: 91.98 USD
- MM2092.10
- MM5087.01
- MM20059.76
- RSI 1452.8
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
+8.92%
200-day average slope, 3 months
+24.12%
50-day average slope, 1 month
+6.16%
Price structure
higher-low
Bullish RSI divergence
No
20-day volatility
2.92 % per day
Volatility change
-4.61%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | 2.01 (9) | 2.40 (13) | 859 (15) | 246 (7) | 162 (11) |
| 2027 | 2.49 (9) | 3.06 (13) | 1 087 (15) | 321 (7) | 211 (10) |
Amounts in millions of USD, EPS in USD per share. In brackets, the number of analysts. Consensus as of September 22, 2026.
Same sub-industry: 77 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | HNGE | 7.0 | 7.2 | 7.4Md USD | 72.8x | 14.8 % | 53.0 % | 29.3 % | — | 3.8 % | 57.9 % | ||
| 2 | CI | 7.0 | 7.1 | 70.9Md USD | 11.1x | 2.3 % | 6.5 % | 9.3 % | 1.8x | 12.9 % | -8.0 % | ||
| 3 | LH | 6.7 | 5.9 | 24.7Md USD | 25.1x | 7.0 % | 5.8 % | 6.8 % | 2.4x | 4.7 % | 10.4 % | ||
| 4 | CVS | 6.6 | 5.9 | 110Md USD | 22.7x | 1.2 % | 7.2 % | 3.2 % | 4.1x | 10.7 % | 10.9 % | ||
| 5 | DVA | 6.6 | 6.5 | 11.7Md USD | 15.4x | 5.9 % | 5.2 % | 6.9 % | 4.5x | 13.8 % | 32.3 % | ||
| 6 | DGX | 6.5 | 5.9 | 25.7Md USD | 24.7x | 9.2 % | 10.2 % | 7.9 % | 2.8x | 5.2 % | 26.9 % | ||
| 7 | BTSG | 6.4 | 4.9 | 11.0Md USD | 41.7x | 1.7 % | 23.0 % | 5.7 % | 4.6x | 3.6 % | 102.1 % | ||
| 8 | FME | 5.3 | 6.7 | 12.0Md USD | 11.8x | 4.8 % | 1.4 % | 4.3 % | 2.7x | 17.0 % | -10.0 % | ||
| 9 | GH | 4.7 | 2.6 | 23.7Md USD | Not meaningful (loss) | -38.3 % | 44.3 % | -37.0 % | -1.5x | -1.0 % | 189.0 % |
